Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Oct;9(10):2165-77.
doi: 10.4161/hv.24941. Epub 2013 Jun 4.

Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

Cindy Tamminga  1 , Martha Sedegah  1 , Santina Maiolatesi  1 , Charlotte Fedders  1 , Sharina Reyes  1 , Anatalio Reyes  1 , Carlos Vasquez  1 , Yolanda Alcorta  1 , Ilin Chuang  1 , Michele Spring  2 , Michael Kavanaugh  3 , Harini Ganeshan  1 , Jun Huang  1 , Maria Belmonte  1 , Esteban Abot  1 , Arnel Belmonte  1 , Joglenna Banania  1 , Fouzia Farooq  1 , Jittawadee Murphy  4 , Jack Komisar  4 , Nancy O Richie  4 , Jason Bennett  4 , Keith Limbach  1 , Noelle B Patterson  1 , Joseph T Bruder  5 , Meng Shi  4 , Edward Miller  3 , Sheetij Dutta  4 , Carter Diggs  6 , Lorraine A Soisson  6 , Michael R Hollingdale  1 , Judith E Epstein  1 , Thomas L Richie  1
Affiliations
Clinical Trial

Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

Cindy Tamminga et al. Hum Vaccin Immunother. 2013 Oct.

Abstract

Background: In a prior study, a DNA prime / adenovirus boost vaccine (DNA/Ad) expressing P. falciparum circumsporozoite protein (CSP) and apical membrane antigen-1 (AMA1) (NMRC-M3V-D/Ad-PfCA Vaccine) induced 27% protection against controlled human malaria infection (CHMI). To investigate the contribution of DNA priming, we tested the efficacy of adenovirus vaccine alone (NMRC-M3V-Ad-PfCA ) in a Phase 1 clinical trial.

Methodology/principal findings: The regimen was a single intramuscular injection with two non-replicating human serotype 5 adenovectors encoding CSP and AMA1, respectively. One x 10 (10) particle units of each construct were combined prior to administration. The regimen was safe and well-tolerated. Four weeks later, 18 study subjects received P. falciparum CHMI administered by mosquito bite. None were fully protected although one showed delayed onset of parasitemia. Antibody responses were low, with geometric mean CSP ELISA titer of 381 (range<50-1626) and AMA1 ELISA of 4.95 µg/mL (range 0.2-38). Summed ex vivo IFN-γ ELISpot responses to overlapping peptides were robust, with geometric mean spot forming cells/million peripheral blood mononuclear cells [sfc/m] for CSP of 273 (range 38-2550) and for AMA1 of 1303 (range 435-4594). CD4+ and CD8+ T cell IFN-γ responses to CSP were positive by flow cytometry in 25% and 56% of the research subjects, respectively, and to AMA1 in 94% and 100%, respectively.

Significance: In contrast to DNA/Ad, Ad alone did not protect against CHMI despite inducing broad, cell-mediated immunity, indicating that DNA priming is required for protection by the adenovirus-vectored vaccine. ClinicalTrials.gov Identifier: NCT00392015.

Trial registration: ClinicalTrials.gov NCT00392015 NCT00870987.

Keywords: T cells; adenovirus; antibody; efficacy; malaria; vaccine.

PubMed Disclaimer

Figures

None
Figure 1. Schematic of Adenovirus CSP and AMA1 vaccines. Each panel presents the native protein (top of each panel) and the protein expressed by the Ad construct (bottom of each panel) for the CSP (A) and AMA1 (B) vaccine antigens. N = N-terminus; C = carboxy terminus; TM = transmembrane domain. Identical colors indicate identical sequences.
None
Figure 2. Trial design. Subjects were immunized week 0 and challenged week 4. Samples for measuring cell-mediated immunity (ELISpot assay and flow cytometry) and antibody levels (ELISA and IFA) were collected at six time points (black arrows): Pre (pre-immunization), Post-Ad (*22–23 d after immunization), Post-Ch+4 (four weeks after challenge), Post-Ch+12 (12 weeks after challenge), Post-Ch+20 (20 weeks after challenge), and Post-Ch+48 (48 weeks after challenge).
None
Figure 3. Flow diagram of immunized and control volunteers. Thirty-seven volunteers met all eligibility criteria of whom 11 withdrew consent, and 26 volunteers were allocated to the immunization group (n = 20) and infectivity controls (n = 6) respectively. Two immunized volunteers were not challenged due to family reasons and poor compliance, respectively. Approximately two years after challenge, an infectivity control died of causes unrelated to the vaccine.
None
Figure 4. Development of parasitemia in the immunized and infectivity volunteers. Parasitemia-free survival curves (Kaplan-Meier) for immunized volunteers and infectivity controls based on microscopic examination of peripheral blood smears.
None
Figure 5. Antibody responses by ELISA to CSP and AMA1. Group geomean CSP and AMA1 ELISA activities for the 18 recipients were significantly higher than baseline (*) CSP: Post-Ad (CSP p = < 0.0001), Post-Ch+4 CSP (p = < 0.0001), Post-Ch+12 (CSP p = < 0.0001) and Post-Ch+20 (CSP p = 0.0003); AMA1: Post-Ad (p = < 0.0001), Post-Ch+4 CSP (p = < 0.0001), Post-Ch+12 (p = < 0.0001) and Post-Ch+20 (p = < 0.0001). For explanation of box plots (including outliers) see statistics section at the end of Methods below.
None
Figure 6. Antibody responses by IFA to P. falciparum sporozoites and asexual blood stages. Group geomean IFA activities were significantly higher than baseline (*): Sporozoites: Post-Ad (p = 0. < 0001), Post-Ch+4 (p = 0. < 0001), Post-Ch+12 (p = 0.0015), Post-Ch+20 (p = 0.0002); red blood stages: Post-Ad (p = < 0.0001), Post-Ch+4 (p = < 0.0001), and Post-Ch+12 (p = < 0.0001) and Post-Ch+20 (p = < 0.0001) (mixed linear model). For explanation of box plots (including outliers) see statistics section at the end of Methods below.
None
Figure 7. Ex vivo T cell IFN-γ activities by ELISpot Assay for CSP and AMA1. Group geomean IFA activities were significantly higher than baseline (*): CSP: Post-Ad (p = < 0.0001), Post-Ch+4 (p = < 0.0001), Post-Ch+12 (p = 0.0083), Post-Ch+20 (p = 0.0009) Post Ch+48 (p = < 0.0001; AMA1 Post-Ad (p = < 0.0001), Post-Ch+4 (p = < 0.0001), Post-Ch+12 (p = 0.0056), Post-Ch+20 (p = 0.0019), Post Ch+48 (p = < 0.0013). For explanation of box plots (including outliers) see statistics section at the end of Methods below.
None
Figure 8. CD4+ and CD8+ T cell IFN-γ activities by flow cytometry for CSP and AMA1. The box plots represent IFN-γ-producing CD4+ or CD8+ T cell frequencies as percentage of gated CD4+ or CD8+ T cells, measured by flow cytometry assays after stimulation with a single CSP or AMA1 megapool containing all individual peptide pools for each antigen. Arrow denotes v156 who had very high CD8+ T cell activity to AMA1 (2.08%) at Post-Ad. IFN-γ-producing CD4+ T cell activities for CSP were only significantly higher than baseline (*) at Post-Ad (p = 0.0017); CD4+ T cell activities for AMA1 were significantly higher than baseline (*) Post-Ad (p = 0.0002), Post-Ch+4 (p = 0.0017), Post-Ch+20 (p = 0.0054) and Post-Ch+48 (p = 0.0035). IFN-γ-producing CD8+ T cell activities for CSP were only marginally higher than baseline (*) at Post Ad (p = 0.07); CD8+ T cell activities for AMA1 were significantly higher than baseline (*) at Post-Ad (p = 0.0021) and Post-Ch+4 (p = 0.017). For explanation of box plots (including outliers) see statistics section at the end of Methods below.
See this image and copyright information in PMC

Similar articles

  • DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
    Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, Richie TL. Chuang I, et al. PLoS One. 2013;8(2):e55571. doi: 10.1371/journal.pone.0055571. Epub 2013 Feb 14. PLoS One. 2013. PMID: 23457473 Free PMC article. Clinical Trial.
  • Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component.
    Tamminga C, Sedegah M, Regis D, Chuang I, Epstein JE, Spring M, Mendoza-Silveiras J, McGrath S, Maiolatesi S, Reyes S, Steinbeiss V, Fedders C, Smith K, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Murphy J, Komisar J, Williams J, Shi M, Brambilla D, Manohar N, Richie NO, Wood C, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Diggs C, Soisson L, Carucci D, Levine G, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL. Tamminga C, et al. PLoS One. 2011;6(10):e25868. doi: 10.1371/journal.pone.0025868. Epub 2011 Oct 7. PLoS One. 2011. PMID: 22003411 Free PMC article. Clinical Trial.
  • Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.
    Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, Lejano J, Abot E, Banania GJ, Sayo R, Farooq F, Belmonte M, Manohar N, Richie NO, Wood C, Long CA, Regis D, Williams FT, Shi M, Chuang I, Spring M, Epstein JE, Mendoza-Silveiras J, Limbach K, Patterson NB, Bruder JT, Doolan DL, King CR, Soisson L, Diggs C, Carucci D, Dutta S, Hollingdale MR, Ockenhouse CF, Richie TL. Sedegah M, et al. PLoS One. 2011;6(10):e24586. doi: 10.1371/journal.pone.0024586. Epub 2011 Oct 7. PLoS One. 2011. PMID: 22003383 Free PMC article. Clinical Trial.
  • Prime-boost vectored malaria vaccines: progress and prospects.
    Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, Goodman A, Nicosia A, Folgori A, Colloca S, Cortese R, Gilbert SC, Draper SJ. Hill AV, et al. Hum Vaccin. 2010 Jan;6(1):78-83. doi: 10.4161/hv.6.1.10116. Epub 2010 Jan 18. Hum Vaccin. 2010. PMID: 20061802 Review.
  • Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
    Heppner DG Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garçon N, Tucker K, Wittes J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J. Heppner DG Jr, et al. Vaccine. 2005 Mar 18;23(17-18):2243-50. doi: 10.1016/j.vaccine.2005.01.142. Vaccine. 2005. PMID: 15755604 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Overstreet MG, Cockburn IA, Chen YC, Zavala F. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an ‘unnatural’ immune response. Immunol Rev. 2008;225:272–83. doi: 10.1111/j.1600-065X.2008.00671.x. - DOI - PMC - PubMed
    1. Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe. 2011;9:451–62. doi: 10.1016/j.chom.2011.05.008. - DOI - PMC - PubMed
    1. Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J. 2009;8:312. doi: 10.1186/1475-2875-8-312. - DOI - PMC - PubMed
    1. Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines. 2011;10:355–64. doi: 10.1586/erv.11.7. - DOI - PubMed
    1. Sedegah M, Tamminga C, McGrath S, House B, Ganeshan H, Lejano J, et al. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One. 2011;6:e24586. doi: 10.1371/journal.pone.0024586. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data

-